Jiang Zhong PharmaceuticalLtd Beheer

Beheer criteriumcontroles 3/4

De CEO Jiang Zhong PharmaceuticalLtd is Wenbin Xiao, benoemd in Mar2022, heeft een ambtstermijn van 2.67 jaar. bezit rechtstreeks 0.015% van de aandelen van het bedrijf, ter waarde CN¥ 1.99M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.7 jaar en 1 jaar.

Belangrijke informatie

Wenbin Xiao

Algemeen directeur

CN¥1.4m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	2.7yrs
Eigendom CEO	0.02%
Management gemiddelde ambtstermijn	4.7yrs
Gemiddelde ambtstermijn bestuur	less than a year

Recente managementupdates

Recent updates

CEO

Wenbin Xiao (44 yo)

2.7yrs

Tenure

CN¥1,408,800

Compensatie

Mr. Wenbin Xiao serves as General Manager at Jiang Zhong Pharmaceutical Co.,Ltd since March 23, 2022. Mr. Wenbin Xiao served as Deputy General Manager at Jiang Zhong Pharmaceutical Co., Ltd., He served as...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Wenbin Xiao	General Manager	2.7yrs	CN¥1.41m	0.015% CN¥ 2.0m
Xiaojun Li	Financial Controller & Financial Director	4.7yrs	CN¥709.70k	0.011% CN¥ 1.5m
Jing Tian Yong	Secretary of the Board of Directors	9.5yrs	CN¥541.60k	0.011% CN¥ 1.5m

4.7yrs

Gemiddelde duur

42yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 600750 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Wei Quan Liu	Chairman	15.2yrs	geen gegevens	0.035% CN¥ 4.5m
Na Tang	Director	2yrs	geen gegevens	geen gegevens
Lian Jin Hong	Independent Director	5.9yrs	CN¥93.30k	geen gegevens
Rong Deng	Director	less than a year	geen gegevens	geen gegevens
Jian Xing	Independent Director	4.5yrs	geen gegevens	0.034% CN¥ 4.4m
Fengxiang Hu	Director	2.3yrs	geen gegevens	0.029% CN¥ 3.8m
Yan Zhang	Independent Director	less than a year	geen gegevens	geen gegevens
Bo Liang	Independent Director	less than a year	geen gegevens	geen gegevens
Wenduo Wen	Director	less than a year	geen gegevens	geen gegevens
Jiao Zhou	Chairman of Supervisory Board	less than a year	geen gegevens	geen gegevens
Dinghai Wang	Supervisor	less than a year	geen gegevens	geen gegevens
Xiaoxia Peng	Employee Supervisor	less than a year	geen gegevens	geen gegevens

1.0yrs

Gemiddelde duur

48.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 600750 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1 jaar), wat duidt op een nieuw bestuur.

Jiang Zhong PharmaceuticalLtd Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Jiang Zhong Pharmaceutical Co.,Ltd, Annual General Meeting, May 17, 2024

Jiang Zhong Pharmaceutical Co.,Ltd, Annual General Meeting, May 17, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.23 (vs CN¥0.23 in 3Q 2023)

Upcoming dividend of CN¥0.50 per share

Investor sentiment improves as stock rises 22%

Jiang Zhong Pharmaceutical Co.,Ltd to Report Q3, 2024 Results on Oct 26, 2024

Second quarter 2024 earnings released: EPS: CN¥0.35 (vs CN¥0.32 in 2Q 2023)

Jiang Zhong Pharmaceutical Co.,Ltd to Report First Half, 2024 Results on Aug 22, 2024

Now 25% undervalued

Now 20% overvalued after recent price rise

Now 21% overvalued after recent price rise

First quarter 2024 earnings released: EPS: CN¥0.43 (vs CN¥0.38 in 1Q 2023)

Jiang Zhong Pharmaceutical Co.,Ltd, Annual General Meeting, May 17, 2024

Jiang Zhong Pharmaceutical Co.,Ltd, Annual General Meeting, May 17, 2024

Jiang Zhong Pharmaceutical Co.,Ltd to Report Q1, 2024 Results on Apr 27, 2024

Full year 2023 earnings released: EPS: CN¥1.12 (vs CN¥0.94 in FY 2022)

Jiang Zhong Pharmaceutical Co.,Ltd to Report Fiscal Year 2023 Results on Mar 23, 2024

Third quarter 2023 earnings released: EPS: CN¥0.23 (vs CN¥0.18 in 3Q 2022)

Jiang Zhong Pharmaceutical Co.,Ltd to Report Q3, 2023 Results on Oct 28, 2023

Second quarter 2023 earnings released: EPS: CN¥0.32 (vs CN¥0.33 in 2Q 2022)

Less than half of directors are independent

Full year 2022 earnings released: EPS: CN¥0.94 (vs CN¥0.80 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.23 in 3Q 2021)

China Resources Pharmaceutical Group Limited Provides Earnings Forecasts for the Nine Months Ended 30 September 2022

Second quarter 2022 earnings released: EPS: CN¥0.33 (vs CN¥0.24 in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.29 (vs CN¥0.25 in 1Q 2021)

Third quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.20 in 3Q 2020)

Jiang Zhong Pharmaceutical Co.,Ltd (SHSE:600750) entered in a contract to acquire 36% stake in Jincheng Haisi Pharmacy Limited Company from Jinneng Holding Equipment Manufacturing Group Co., Ltd. and Jincheng Wangtai Technology Industry and Trade Co., Ltd for approximately CNY 120 million.

Second quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.22 in 2Q 2020)

Investor sentiment improved over the past week

Jiang Zhong Pharmaceutical Co.,Ltd (SHSE:600750) announces an Equity Buyback for 7,000,000 shares, representing 1.11% for CNY 115.5 million.

First quarter 2021 earnings released: EPS CN¥0.25 (vs CN¥0.21 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.75 (vs CN¥0.73 in FY 2019)

New 90-day low: CN¥10.34

Jiang Zhong Pharmaceutical Co.,Ltd to Report Fiscal Year 2020 Results on Mar 20, 2021

New 90-day low: CN¥10.89

New 90-day low: CN¥11.55

Third quarter earnings released

New 90-day low: CN¥11.81

Earnings released

Jiangzhong Pharmaceutical Co., Ltd to Report First Half, 2020 Results on Aug 26, 2020

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd